Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
You could win a cash prize of up to £25,000 when you play the JDRF lottery. As well as the chance to win great prizes, you'll also help fund our research to find a cure for type 1 diabetes.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join us on Saturday 21 September 2024 with hundreds of JDRF supporters celebrating One Walk Belfast!
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF is undergoing a transformation.We are becoming Breakthrough T1D in October.
Home > News & events > News > New autoimmune research charity joins the Connect Immune Research partnership
Juvenile Arthritis Research, a charity focused on the autoimmune condition juvenile idiopathic arthritis (JIA), becomes the 12th member of the Connect Immune Research partnership.
Established in 2018, Connect Immune Research is a collaborative initiative that aims to unpick the root causes of autoimmunity, where the immune system mistakenly attacks our own healthy cells. The partnership enables scientists to think beyond individual autoimmune conditions and explore overlapping causes of autoimmunity. This tactic boosts our potential of developing new treatments for a range of conditions including type 1 diabetes, multiple sclerosis and arthritis.
JIA is a rheumatic condition – meaning chronic joint pain – that begins before children are 16 years old. It happens when the immune system attacks and damages the joints, resulting in pain and mobility issues. Although JIA begins in childhood and adolescence, it is a lifelong condition. We have immune therapies that can target the symptoms of JIA, but not the underlying causes. Juvenile Arthritis Research is a parent-led charity committed to finding a cure for JIA.
Richard Beesley, Founder of Juvenile Arthritis Research, said: “When I first founded Juvenile Arthritis Research five years ago it was with the expectation that some of the clues to better understanding Juvenile Idiopathic Arthritis, and some of the knowledge to develop better treatments, would be by working closely with other autoimmune disease areas. That’s why I am delighted that we are joining the Connect Immune Research partnership, with the aim to continue to transform lives through working with others, sharing knowledge and ideas, and making a better future for the children, young people, adults and families we support.”
Dr Caroline Schmutz, Head of Research Partnerships at JDRF UK, said: “We are excited to welcome Juvenile Arthritis Research as our newest Connect Immune Research member. Their collaborative approach to research and confidence in the benefits of combining research across different disease areas make Juvenile Arthritis Research an ideal partner. The more research organisations we have studying the biological mechanisms driving autoimmunity, the sooner we will develop new treatments and cures for multiple autoimmune conditions.”
Find out more about our Connect Immune Research partnership.
Learn about British Thyroid Foundation (BTF) joining Connect Immune Research.
Learn about Professor Lucy Walker's research project, funded through Connect Immune Research.
New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.
We wrote to the producers of the hit BBC show after they broadcast jokes about type 1 diabetes.
Parliamentary Inquiry chaired by our Global Health Ambassador, Rt. Hon Theresa May MP and Sir George Howarth MP, highlights the risks of type 1 diabetes-related eating disorders (T1DE).
In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.
Immunotherapy, beta cell replacement, smart insulins – we’re driving research in the most promising areas to find cures and better treatments for type 1 diabetes.
